 | • レポートコード：MRC2-11QY04097 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は希少性肺疾患治療のグローバル市場について調査・分析したレポートです。種類別（免疫抑制剤、抗炎症薬、抗線維化剤、血管拡張剤、コルチコステロイド、CFTRモジュレーター、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別希少性肺疾患治療の競争状況、市場シェア ・世界の希少性肺疾患治療市場：種類別市場規模 2015年-2020年（免疫抑制剤、抗炎症薬、抗線維化剤、血管拡張剤、コルチコステロイド、CFTRモジュレーター、その他） ・世界の希少性肺疾患治療市場：種類別市場規模予測 2021年-2026年（免疫抑制剤、抗炎症薬、抗線維化剤、血管拡張剤、コルチコステロイド、CFTRモジュレーター、その他） ・世界の希少性肺疾患治療市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界の希少性肺疾患治療市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米の希少性肺疾患治療市場分析：米国、カナダ ・ヨーロッパの希少性肺疾患治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの希少性肺疾患治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の希少性肺疾患治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの希少性肺疾患治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GSK、Pfizer、Celgene、Novartis、NPS Pharmaceuticals、Auspex Pharmaceuticals、Synageva BioPharma、Roche、Sanofi ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists.
Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are endemic to regions mainly in Africa, Asia and the Americas.
Market Analysis and Insights: Global Orphan Lung Diseases Treatment Market
The global Orphan Lung Diseases Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Orphan Lung Diseases Treatment Scope and Market Size
Orphan Lung Diseases Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Orphan Lung Diseases Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
GSK
Pfizer
Celgene
Novartis
NPS Pharmaceuticals
Auspex Pharmaceuticals
Synageva BioPharma
Roche
Sanofi
Market segment by Type, the product can be split into
Immunosuppressants
Anti-Inflammatory Drugs
Anti-Fibrotic Agents
Vasodilators
Corticosteroids
CFTR Modulators
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Orphan Lung Diseases Treatment Revenue
1.4 Market by Type
1.4.1 Global Orphan Lung Diseases Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Immunosuppressants
1.4.3 Anti-Inflammatory Drugs
1.4.4 Anti-Fibrotic Agents
1.4.5 Vasodilators
1.4.6 Corticosteroids
1.4.7 CFTR Modulators
1.4.8 Others
1.5 Market by Application
1.5.1 Global Orphan Lung Diseases Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Orphan Lung Diseases Treatment Market Perspective (2015-2026)
2.2 Global Orphan Lung Diseases Treatment Growth Trends by Regions
2.2.1 Orphan Lung Diseases Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Orphan Lung Diseases Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Orphan Lung Diseases Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Orphan Lung Diseases Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Orphan Lung Diseases Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Orphan Lung Diseases Treatment Players by Market Size
3.1.1 Global Top Orphan Lung Diseases Treatment Players by Revenue (2015-2020)
3.1.2 Global Orphan Lung Diseases Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Orphan Lung Diseases Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Orphan Lung Diseases Treatment Market Concentration Ratio
3.2.1 Global Orphan Lung Diseases Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Orphan Lung Diseases Treatment Revenue in 2019
3.3 Orphan Lung Diseases Treatment Key Players Head office and Area Served
3.4 Key Players Orphan Lung Diseases Treatment Product Solution and Service
3.5 Date of Enter into Orphan Lung Diseases Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Orphan Lung Diseases Treatment Historic Market Size by Type (2015-2020)
4.2 Global Orphan Lung Diseases Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
5.2 Global Orphan Lung Diseases Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Orphan Lung Diseases Treatment Market Size (2015-2020)
6.2 Orphan Lung Diseases Treatment Key Players in North America (2019-2020)
6.3 North America Orphan Lung Diseases Treatment Market Size by Type (2015-2020)
6.4 North America Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Orphan Lung Diseases Treatment Market Size (2015-2020)
7.2 Orphan Lung Diseases Treatment Key Players in Europe (2019-2020)
7.3 Europe Orphan Lung Diseases Treatment Market Size by Type (2015-2020)
7.4 Europe Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
8 China
8.1 China Orphan Lung Diseases Treatment Market Size (2015-2020)
8.2 Orphan Lung Diseases Treatment Key Players in China (2019-2020)
8.3 China Orphan Lung Diseases Treatment Market Size by Type (2015-2020)
8.4 China Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Orphan Lung Diseases Treatment Market Size (2015-2020)
9.2 Orphan Lung Diseases Treatment Key Players in Japan (2019-2020)
9.3 Japan Orphan Lung Diseases Treatment Market Size by Type (2015-2020)
9.4 Japan Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Orphan Lung Diseases Treatment Market Size (2015-2020)
10.2 Orphan Lung Diseases Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Orphan Lung Diseases Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
11 India
11.1 India Orphan Lung Diseases Treatment Market Size (2015-2020)
11.2 Orphan Lung Diseases Treatment Key Players in India (2019-2020)
11.3 India Orphan Lung Diseases Treatment Market Size by Type (2015-2020)
11.4 India Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Orphan Lung Diseases Treatment Market Size (2015-2020)
12.2 Orphan Lung Diseases Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Orphan Lung Diseases Treatment Market Size by Type (2015-2020)
12.4 Central & South America Orphan Lung Diseases Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 GSK
13.1.1 GSK Company Details
13.1.2 GSK Business Overview
13.1.3 GSK Orphan Lung Diseases Treatment Introduction
13.1.4 GSK Revenue in Orphan Lung Diseases Treatment Business (2015-2020))
13.1.5 GSK Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview
13.2.3 Pfizer Orphan Lung Diseases Treatment Introduction
13.2.4 Pfizer Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 Celgene
13.3.1 Celgene Company Details
13.3.2 Celgene Business Overview
13.3.3 Celgene Orphan Lung Diseases Treatment Introduction
13.3.4 Celgene Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.3.5 Celgene Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview
13.4.3 Novartis Orphan Lung Diseases Treatment Introduction
13.4.4 Novartis Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 NPS Pharmaceuticals
13.5.1 NPS Pharmaceuticals Company Details
13.5.2 NPS Pharmaceuticals Business Overview
13.5.3 NPS Pharmaceuticals Orphan Lung Diseases Treatment Introduction
13.5.4 NPS Pharmaceuticals Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.5.5 NPS Pharmaceuticals Recent Development
13.6 Auspex Pharmaceuticals
13.6.1 Auspex Pharmaceuticals Company Details
13.6.2 Auspex Pharmaceuticals Business Overview
13.6.3 Auspex Pharmaceuticals Orphan Lung Diseases Treatment Introduction
13.6.4 Auspex Pharmaceuticals Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.6.5 Auspex Pharmaceuticals Recent Development
13.7 Synageva BioPharma
13.7.1 Synageva BioPharma Company Details
13.7.2 Synageva BioPharma Business Overview
13.7.3 Synageva BioPharma Orphan Lung Diseases Treatment Introduction
13.7.4 Synageva BioPharma Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.7.5 Synageva BioPharma Recent Development
13.8 Roche
13.8.1 Roche Company Details
13.8.2 Roche Business Overview
13.8.3 Roche Orphan Lung Diseases Treatment Introduction
13.8.4 Roche Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.8.5 Roche Recent Development
13.9 Sanofi
13.9.1 Sanofi Company Details
13.9.2 Sanofi Business Overview
13.9.3 Sanofi Orphan Lung Diseases Treatment Introduction
13.9.4 Sanofi Revenue in Orphan Lung Diseases Treatment Business (2015-2020)
13.9.5 Sanofi Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Orphan Lung Diseases Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Orphan Lung Diseases Treatment Revenue
Table 3. Ranking of Global Top Orphan Lung Diseases Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Orphan Lung Diseases Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Immunosuppressants
Table 6. Key Players of Anti-Inflammatory Drugs
Table 7. Key Players of Anti-Fibrotic Agents
Table 8. Key Players of Vasodilators
Table 9. Key Players of Corticosteroids
Table 10. Key Players of CFTR Modulators
Table 11. Key Players of Others
Table 12. Global Orphan Lung Diseases Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Orphan Lung Diseases Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Orphan Lung Diseases Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Orphan Lung Diseases Treatment Market Share by Regions (2015-2020)
Table 16. Global Orphan Lung Diseases Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Orphan Lung Diseases Treatment Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Orphan Lung Diseases Treatment Market Growth Strategy
Table 22. Main Points Interviewed from Key Orphan Lung Diseases Treatment Players
Table 23. Global Orphan Lung Diseases Treatment Revenue by Players (2015-2020) (Million US$)
Table 24. Global Orphan Lung Diseases Treatment Market Share by Players (2015-2020)
Table 25. Global Top Orphan Lung Diseases Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Orphan Lung Diseases Treatment as of 2019)
Table 26. Global Orphan Lung Diseases Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Orphan Lung Diseases Treatment Product Solution and Service
Table 29. Date of Enter into Orphan Lung Diseases Treatment Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 32. Global Orphan Lung Diseases Treatment Market Size Share by Type (2015-2020)
Table 33. Global Orphan Lung Diseases Treatment Revenue Market Share by Type (2021-2026)
Table 34. Global Orphan Lung Diseases Treatment Market Size Share by Application (2015-2020)
Table 35. Global Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 36. Global Orphan Lung Diseases Treatment Market Size Share by Application (2021-2026)
Table 37. North America Key Players Orphan Lung Diseases Treatment Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Orphan Lung Diseases Treatment Market Share (2019-2020)
Table 39. North America Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 40. North America Orphan Lung Diseases Treatment Market Share by Type (2015-2020)
Table 41. North America Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 42. North America Orphan Lung Diseases Treatment Market Share by Application (2015-2020)
Table 43. Europe Key Players Orphan Lung Diseases Treatment Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Orphan Lung Diseases Treatment Market Share (2019-2020)
Table 45. Europe Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Orphan Lung Diseases Treatment Market Share by Type (2015-2020)
Table 47. Europe Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Orphan Lung Diseases Treatment Market Share by Application (2015-2020)
Table 49. China Key Players Orphan Lung Diseases Treatment Revenue (2019-2020) (Million US$)
Table 50. China Key Players Orphan Lung Diseases Treatment Market Share (2019-2020)
Table 51. China Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 52. China Orphan Lung Diseases Treatment Market Share by Type (2015-2020)
Table 53. China Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 54. China Orphan Lung Diseases Treatment Market Share by Application (2015-2020)
Table 55. Japan Key Players Orphan Lung Diseases Treatment Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Orphan Lung Diseases Treatment Market Share (2019-2020)
Table 57. Japan Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Orphan Lung Diseases Treatment Market Share by Type (2015-2020)
Table 59. Japan Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Orphan Lung Diseases Treatment Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Orphan Lung Diseases Treatment Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Orphan Lung Diseases Treatment Market Share (2019-2020)
Table 63. Southeast Asia Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Orphan Lung Diseases Treatment Market Share by Type (2015-2020)
Table 65. Southeast Asia Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Orphan Lung Diseases Treatment Market Share by Application (2015-2020)
Table 67. India Key Players Orphan Lung Diseases Treatment Revenue (2019-2020) (Million US$)
Table 68. India Key Players Orphan Lung Diseases Treatment Market Share (2019-2020)
Table 69. India Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 70. India Orphan Lung Diseases Treatment Market Share by Type (2015-2020)
Table 71. India Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 72. India Orphan Lung Diseases Treatment Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Orphan Lung Diseases Treatment Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Orphan Lung Diseases Treatment Market Share (2019-2020)
Table 75. Central & South America Orphan Lung Diseases Treatment Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Orphan Lung Diseases Treatment Market Share by Type (2015-2020)
Table 77. Central & South America Orphan Lung Diseases Treatment Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Orphan Lung Diseases Treatment Market Share by Application (2015-2020)
Table 79. GSK Company Details
Table 80. GSK Business Overview
Table 81. GSK Product
Table 82. GSK Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 83. GSK Recent Development
Table 84. Pfizer Company Details
Table 85. Pfizer Business Overview
Table 86. Pfizer Product
Table 87. Pfizer Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 88. Pfizer Recent Development
Table 89. Celgene Company Details
Table 90. Celgene Business Overview
Table 91. Celgene Product
Table 92. Celgene Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 93. Celgene Recent Development
Table 94. Novartis Company Details
Table 95. Novartis Business Overview
Table 96. Novartis Product
Table 97. Novartis Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 98. Novartis Recent Development
Table 99. NPS Pharmaceuticals Company Details
Table 100. NPS Pharmaceuticals Business Overview
Table 101. NPS Pharmaceuticals Product
Table 102. NPS Pharmaceuticals Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 103. NPS Pharmaceuticals Recent Development
Table 104. Auspex Pharmaceuticals Company Details
Table 105. Auspex Pharmaceuticals Business Overview
Table 106. Auspex Pharmaceuticals Product
Table 107. Auspex Pharmaceuticals Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 108. Auspex Pharmaceuticals Recent Development
Table 109. Synageva BioPharma Company Details
Table 110. Synageva BioPharma Business Overview
Table 111. Synageva BioPharma Product
Table 112. Synageva BioPharma Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 113. Synageva BioPharma Recent Development
Table 114. Roche Business Overview
Table 115. Roche Product
Table 116. Roche Company Details
Table 117. Roche Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 118. Roche Recent Development
Table 119. Sanofi Company Details
Table 120. Sanofi Business Overview
Table 121. Sanofi Product
Table 122. Sanofi Revenue in Orphan Lung Diseases Treatment Business (2015-2020) (Million US$)
Table 123. Sanofi Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Orphan Lung Diseases Treatment Market Share by Type: 2020 VS 2026
Figure 2. Immunosuppressants Features
Figure 3. Anti-Inflammatory Drugs Features
Figure 4. Anti-Fibrotic Agents Features
Figure 5. Vasodilators Features
Figure 6. Corticosteroids Features
Figure 7. CFTR Modulators Features
Figure 8. Others Features
Figure 9. Global Orphan Lung Diseases Treatment Market Share by Application: 2020 VS 2026
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. Orphan Lung Diseases Treatment Report Years Considered
Figure 14. Global Orphan Lung Diseases Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Orphan Lung Diseases Treatment Market Share by Regions: 2020 VS 2026
Figure 16. Global Orphan Lung Diseases Treatment Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Orphan Lung Diseases Treatment Market Share by Players in 2019
Figure 19. Global Top Orphan Lung Diseases Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Orphan Lung Diseases Treatment as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Orphan Lung Diseases Treatment Revenue in 2019
Figure 21. North America Orphan Lung Diseases Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Orphan Lung Diseases Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Orphan Lung Diseases Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Orphan Lung Diseases Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Orphan Lung Diseases Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Orphan Lung Diseases Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Orphan Lung Diseases Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
慢性肺疾患治療の世界市場（～2026年） Lung disease is a very common medical condition that is present in almost every region of the world. Chronic lung diseases can be dangerous and if not treated properly can cause death. The chronic lung diseases cause uneasiness and complications in the respiratory system thus causing difficulty in r…- 希少疾患の世界市場（～2026年） An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases hav…
- 後天性孤児造血疾患治療薬の世界市場（～2026年） Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack …
- 免疫介在性炎症性疾患治療の世界市場（～2026年） Immune-Mediated Inflammatory Diseases Treatment is any of a group of conditions or diseases that lack a definitive etiology, but which are characterized by common inflammatory pathways leading to inflammation, and which may result from, or be triggered by, a dysregulation of the normal immune respon…
- 小細胞肺がん治療の世界市場（～2026年） Market Analysis and Insights: Global Small Cell Lung Cancer Treatment Market The global Small Cell Lung Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Small Cell Lung Cancer Treatment Scope and Market…